Scientists test double hunger blocker for obesity
NCT ID NCT07171723
Summary
This study aims to understand how the body's hunger signals work in people with obesity who are already taking the weight-loss medication semaglutide. Researchers will give 24 participants an experimental compound (LEAP2) that blocks the 'hunger hormone' ghrelin to see if it further reduces appetite and food intake. The goal is to learn if combining different appetite-control methods could lead to better future treatments for obesity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
RECRUITINGHellerup, 2900, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.